MONMOUTH JUNCTION, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, presented positive initial safety data from Phase 1 dose escalation trial of ELU001 (NCT05001282) in a poster titled “ELU-FR?-1: A Study to Evaluate ELU001, a C’Dot Drug Conjugate, in Patients with Solid Tumors that Overexpress Folate Receptor Alpha (FR?)” (abstract #CT255) at the American Association for Cancer Research (AACR) 2023 Annual Meeting. In addition, the company presented new preclinical data in a poster titled “Preclinical development of ELU001 - a folate receptor alpha (FR?)-targeted C’Dot drug conjugate (CDC) for the treatment of brain metastases” (abstract #837).

View post:
Elucida Oncology Announces Positive Early Phase 1 Safety Data Along with Preclinical Data for the Treatment of Brain Metastases for ELU001, an...